Business
Immuron’s commercially available products found to neutralise COVID-19 during in vitro research – Small Caps
Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19.
Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19.
IMM-124E is used in Immurons over-the-counter Travelan and Protectyn products which were developed as immunotherapeutics to prevent travellers diarrhea and other gastrointestinal and digestive issues.
The products are commercially available, with Travelan currently registered for use across Australia, Cana…
-
General19 hours agoZac Lomax released by Eels for ‘opportunities outside NRL’, fuelling speculation of R360 switch
-
Noosa News22 hours agoMore children’s sand products from Kmart and Target recalled over asbestos contamination fears
-
General24 hours agoMore coloured sand products recalled as ACT set to announce when schools will reopen
-
Noosa News23 hours agoBurgess Creek to go weed free